Alprostadil Liposomes for Injection

DRUG3 trials

Sponsors

Guangzhou Yipinhong Pharmaceutical CO.,LTD, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Arteriosclerosis ObliteransCardiovascular DiseasesPeripheral Artery Disease

Phase 1

The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers

CompletedNCT02889822

Guangzhou Yipinhong Pharmaceutical CO.,LTDCardiovascular Diseases

Start: 2010-03-31End: 2010-12-31Updated: 2016-09-13

Phase 2

A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans

Guangzhou Yipinhong Pharmaceutical CO.,LTDArteriosclerosis Obliterans

Start: 2016-08-31End: 2017-12-31Target: 160Updated: 2017-03-10

Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Peripheral Artery Disease

Start: 2019-10-01End: 2021-06-01Target: 20Updated: 2019-12-18